Corezetta, a company specializing in healthcare big data, said Monday that the number of drugs with an annual prescription sale of more than 10 billion won ($9.3 million) is rapidly increasing.

According to the results published, the number of drugs with an annual prescription amount of over 10 billion won increased from 336 in 2013 to 391 in 2016. If the trend had continued, the company expects that more than 400 drugs might have exceeded the annual prescription amount of 10 billion won by last year.

The company analyzed the national patient sample (NPS) big data from the Health Insurance Review and Assessment Service (HIRA) from 2013 to 2016.

The analysis also showed that Atorvastatin, a hyperlipidemia treatment, has the largest share in Korea’s pharmaceutical market with annual prescription sales with 498 billion won as of 2016.

Although no drug recorded an annual prescription sale of 300 billion won, other drugs such as amlodipine, clopidogrel, Na hyaluronate, rosuvastatin, amlopidine-valsartan, donepezil and choline alfoscerate recorded yearly prescription sales of 200 billion won in 2016.

“The unusual point of the data was that out of the drugs that recorded annual prescription sales over 100 billion won of drugs, Trastuzumab was the only treatment without a generic drug,” the company said. “Although the launch of generic drugs lowered drug costs, it increased the prescription amount.”

Corezetta plans to provide annual members of PBD (PharmaBigData), the company’s big data analysis service, with the entire analysis of the report, including a columnar analysis.